Verona Pharma plc - American Depositary Share (VRNA) News
Filter VRNA News Items
VRNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VRNA News Highlights
- For VRNA, its 30 day story count is now at 2.
- Over the past 4 days, the trend for VRNA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DNLI and SRPT are the most mentioned tickers in articles about VRNA.
Latest VRNA News From Around the Web
Below are the latest news stories about VERONA PHARMA PLC that investors may wish to consider to help them evaluate VRNA as an investment opportunity.
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the DayFluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article. |
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024. |
Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to TradeThe consensus price target hints at a 135.9% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP AwardLONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023’ at the SCRIP Awards in recognition of his exemplary leadership. David Zaccardelli, Pharm. D., President and CEO of Verona Pharma said: “I am honored to receive this prestigious award and would like to thank the dedicated and talented team at Verona Pharma for their efforts to bring |
11 Best Undervalued UK Stocks To Buy NowIn this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now. If you want to skip our overview of the British economy, then take a look at 5 Best Undervalued UK Stocks To Buy Now. The U.K. is one of the biggest economies in the world and a […] |
Verona Pharma Announces November 2023 Investor Conference ParticipationLONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the following conferences in November 2023: Jefferies London Healthcare ConferenceDate: Wednesday, November 15, 2023Time: 10:00 AM EST / 3:00 PM GMTLocation: London, UK Piper Sandler 35th Annual Healthcare ConferenceDate: Tuesday, November 28, 2023Time: 8:00 AM EST / 1:00 PM GMTLocation: New York, NY 6 |
Does Verona Pharma PLC American Depositary Share (VRNA) Have the Potential to Rally 119.18% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 119.2% in Verona Pharma PLC American Depositary Share (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Verona Pharma plc (NASDAQ:VRNA) Q3 2023 Earnings Call TranscriptVerona Pharma plc (NASDAQ:VRNA) Q3 2023 Earnings Call Transcript November 4, 2023 Operator: Welcome to Verona Pharma’s Third Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Earlier this morning, Verona Pharma issued a press release announcing its financial results for the three […] |
Insider Sell: Chief Medical Officer Kathleen Rickard Sells 58,752 Shares of Verona Pharma PLCOn November 3, 2023, Kathleen Rickard, the Chief Medical Officer of Verona Pharma PLC (NASDAQ:VRNA), sold 58,752 shares of the company. |
Verona Pharma PLC (VRNA) Reports Q3 2023 Financial Results and Corporate UpdateCompany's cash position strengthens, R&D expenses decrease, and SG&A expenses rise due to commercial launch preparations |